| 变动前股数 | | 变动前比例 | | 变动后股数 | 变动后 | | | 权 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 益变动的 | | | | | | | | | | 投资者名称 | | | | | 权益变动方式 | | | | | （万股） | （万股） | （%） | | | 比例（%） | | | 时间 | | 区间 | | | | | | | | | | | 发生直接持股变动的主体： | | | | | | | | | 苏州纳卓管 | | | | | 集中竞价 ? | | | | | 理咨询合伙 | | | | | ? 大宗交易 | | | 2025/6/4- | | 企业（有限合 | | | | | 其他：____（请 | | | 2025/7/22 | | 伙） | | | | | 注明） | | | | | 苏州纳研管 | | | | | 集中竞价 ? | | | | | 理咨询合伙 | | | | | 大宗交易 ? | | | 2025/6/4- | | 企业（有限合 | | | | | 其他：____（请 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-025 2025 年 7 月 22 日，公司收到股东苏州纳卓管理咨询合伙企业（有限合伙） （以下简称"苏州纳卓"）、苏州纳研管理咨询合伙企业（有限合伙）（以下简称 "苏州纳研"）发来的《关于减持股份暨权益变动触及 1%刻度的告知函》，股东 苏州纳卓、苏州纳研于 2025 年 6 月 4 日至 2025 年 7 月 22 日期间通过集中竞价 及大宗交易方式累计减持所持有的公司股份 1,275,000 股。截止本公告披露日， 股东苏州纳卓持有公司股份 13,612,500 股，占公司总股本的 3.37%；股东苏州 纳研持有公司股份 27,862,500 股，占公司总股本的 6.90%。股东苏州纳卓、苏 州纳研及其一致行动人深圳纳微科技有限公司、江必旺所持公司股份比例由 44.30%减少至 43.98%，触及 1%的整数倍。截至目前，减持计划尚未实施完毕。 具体情况如下： | 投资者名称 | 变动前股数 | 变动前比例 | 变动后股数 | 变动后 | 权益变动方式 | | 权益变动的 | | --- | --- | --- | --- | --- | ...

Core Viewpoint - The report highlights a positive performance in the pharmaceutical sector, particularly in the innovative drug industry, driven by ongoing licensing agreements and supportive domestic policies [3]. Fund Performance - The fund reported a profit of 26.97 million yuan in Q2 2025, with a weighted average profit per fund share of 0.0627 yuan [2]. - The fund's net asset value (NAV) growth rate for Q2 was 7.62%, and the fund size reached 375 million yuan by the end of Q2 [2][16]. - As of July 18, the fund's unit NAV was 0.96 yuan [2]. - The fund's performance over the past three months showed a NAV growth rate of 14.74%, ranking 112 out of 138 comparable funds [4]. - Over the past six months, the fund's NAV growth rate was 25.40%, ranking 100 out of 138 [4]. - The one-year NAV growth rate was 24.99%, also ranking 100 out of 133 [4]. - The three-year NAV growth rate was 4.99%, ranking 46 out of 107 [4]. Investment Strategy - The fund manager expressed optimism about the innovative drug sector, indicating a shift from a general revaluation phase to a stage where actual performance and partnerships will be tested [3]. - The strategy includes a "barbell" approach, focusing on high-probability or high-return innovative drug companies [3]. - The fund is also looking at sectors with strong performance, such as orthopedics and upstream innovative drugs, while making early allocations in improving sectors like medical devices [3]. - New technologies like AI and brain-computer interfaces are expected to transform the healthcare system, although short-term financial impacts on related companies may be limited [3]. Risk and Return Metrics - The fund's three-year Sharpe ratio was 0.1406, ranking 41 out of 105 comparable funds [9]. - The maximum drawdown over the past three years was 29.8%, ranking 97 out of 106 [11]. - The fund's average stock position over the past three years was 85.43%, slightly below the comparable average of 86.95% [14].

Group 1 - The pharmaceutical sector is showing strong performance, particularly in innovative drugs, generic drugs, and animal vaccines, driven by the recent policy changes from the National Healthcare Security Administration [1] - The 11th batch of drug procurement initiated by the National Healthcare Security Administration excludes innovative drugs from the procurement scope, which is expected to protect the profit margins of innovative drug companies [1] - The CXO and research service sectors have seen significant gains, with companies like WuXi AppTec and Boteng Co. reporting substantial Q2 performance increases, indicating a positive trend in the sector [1] Group 2 - The innovative drug sector is identified as the most clearly defined and growth-oriented sub-industry within the pharmaceutical sector, with a recommendation to actively embrace and allocate resources to this area [2] - The rapid growth of License Out transactions is providing substantial cash flow for innovative drug companies, supporting their core pipelines in overseas markets [2] - There is an expectation for continued domestic market share growth for Chinese innovative drugs due to policy support and improved product capabilities, despite foreign companies holding a significant portion of the market [2]

Group 1 - The core viewpoint of the news is that Nanwei Technology is experiencing significant growth in its small molecule application sector, driven by the booming GLP-1 peptide drug market, leading to a notable increase in revenue from chromatography filler products [1] - The company's large molecule business is stabilizing, supported by phase III scaling application projects and changes in commercialized drug projects, despite no significant rise in early-stage R&D demand [1] - Nanwei Technology has enhanced its competitiveness in antibody applications by launching high-performance third-generation soft gel affinity products and optimizing its marketing system [1] Group 2 - In Q2, the company's net profit margin attributable to the parent company improved quarter-on-quarter, primarily due to the high gross margin and significant share of the chromatography filler business [1] - The acquisition of Saipuri Instruments and Fuli Instruments has completed the product line and strengthened the company's full industry chain coverage and service capabilities [1] - To address intense domestic competition, the company is focused on building an overall chromatography technology platform to provide comprehensive solutions and accelerate its overseas market expansion to enhance international competitiveness [1]

Group 1: Nanwei Technology - Nanwei Technology benefits from the explosive growth of the GLP-1 peptide drug market, leading to significant revenue growth in chromatography filler products, which drives rapid development in small molecule business [1] - The company's net profit margin increased quarter-on-quarter in Q2, primarily due to the high gross margin and substantial share of chromatography filler business [1] - Nanwei Technology aims to create a comprehensive chromatography technology platform to provide overall solutions and accelerate overseas market expansion to enhance international competitiveness [1] Group 2: Medicy - Medicy has established a research office in Boston, USA, aiming to increase overseas business share to 40-50% [2] - The company has developed a comprehensive preclinical research service capability in biopharmaceutical R&D and is building multiple biopharmaceutical R&D technology platforms [2] - Medicy's operating costs decreased by 12.46% year-on-year due to cost control measures, and the domestic CRO industry is expected to benefit from policy support for innovative drug development [2] Group 3: Naipu Mining - Naipu Mining's forged composite liners offer significant advantages, including better wear resistance and higher mill efficiency, with successful applications in Tibet's Zhinuola mine [3] - The company plans to promote forged composite liners as a leading product and has agreements with multiple mines, expecting more successful cases by the end of this year and early next year [3] - Naipu Mining has invested in a copper-gold mine project in Colombia, which has completed feasibility design and is expected to have a construction period of two years with a mine life of 14.2 years [3] Group 4: China Ruilin - China Ruilin Engineering Technology Co., Ltd. has a diverse range of core technologies in the non-ferrous metal industry, with overseas business revenue accounting for 41.02% and domestic business revenue for 58.98% in 2024 [4] - The company is progressing with fundraising projects that will enhance its R&D capabilities and core competitiveness [4] - Representative overseas projects include the Abuja water supply project in Nigeria and the expansion of the Bor copper smelting plant in Serbia [4]

Core Viewpoint - Nanwei Technology (688690) is experiencing growth driven by the booming GLP-1 peptide drug market, leading to increased investment in new drug research and production capacity by domestic and international pharmaceutical companies [2][3]. Group 1: Business Performance - The company's main revenue for Q1 2025 was 189 million yuan, a year-on-year increase of 22.39%, with a net profit attributable to shareholders of 29.22 million yuan, up 72.98% year-on-year [7]. - The gross profit margin for the chromatography filler business is high, accounting for approximately 60% of the company's revenue, which has improved overall profitability [4]. Group 2: Market Strategy - The company is focusing on the antibody new drug projects as a key area for replacing imported products, enhancing competitiveness through continuous R&D investment and product innovation [3]. - To address domestic competition, the company is building a comprehensive chromatography technology platform, providing integrated solutions to avoid price wars in single product categories [6]. Group 3: Mergers and Acquisitions - The acquisition of two instrument companies enhances the company's product line from chromatography fillers to protein purification equipment, improving business and product layout and achieving synergy in customer expansion and market sales [5]. Group 4: Future Outlook - The company is accelerating its overseas market layout and enhancing its overseas sales capabilities to increase application opportunities for its filler products among international clients [3][6].

Group 1: Company Performance - Northern Rare Earth expects a net profit of 900 million to 960 million yuan for the first half of 2025, representing a year-on-year increase of 1882.54% to 2014.71% [1] - Muyuan Foods anticipates a net profit of 10.5 billion to 11 billion yuan for the first half of 2025, reflecting a year-on-year growth of 924.6% to 973.39% [2] - Hongta Securities projects a net profit of 651 million to 696 million yuan for the first half of 2025, indicating a year-on-year increase of 45% to 55% [3] Group 2: Business Developments - Dazhihui clarifies that it has not engaged in businesses related to "stablecoins," "virtual asset trading," or "cross-border payments," following a significant stock price fluctuation [4] - Bluetech announces a share transfer agreement where its actual controller will change, with the Ma'anshan Municipal Government becoming the actual controller after the transfer of 18% of shares [5] Group 3: Industry Trends - Jiangsu Electric Power reports a 5.01% year-on-year increase in electricity generation for the first half of 2025 [6] - Jin'an Guoji anticipates a non-recurring net profit growth of 4700% to 6300% for the first half of 2025 [6] - New Beiyang expects a non-recurring net profit growth of 650% to 720% for the first half of 2025 [6]

Group 1 - Morning Light Biological expects a net profit of 202.0 million to 232.0 million yuan for the first half of 2025, representing a year-on-year increase of 102.33% to 132.38% [1] - Northern Rare Earth anticipates a net profit of 900.0 million to 960.0 million yuan for the first half of 2025, with a significant year-on-year growth of 1882.54% to 2014.71% [1] - Youfa Group forecasts a net profit of 277.0 million to 307.0 million yuan for the first half of 2025, reflecting a year-on-year increase of 151.69% to 178.93% [1] Group 2 - Torch Electronics projects a net profit of approximately 247.0 million to 280.0 million yuan for the first half of 2025, indicating a year-on-year growth of 50.36% to 70.45% [3] - Zhiwei Intelligent expects a net profit of 91.98 million to 112.43 million yuan for the first half of 2025, with a year-on-year increase of 62.85% to 99.06% [4] - Youhao Group anticipates a net profit of 12.0 million yuan for the first half of 2025, representing a year-on-year growth of 51% [5] Group 3 - Nami Technology expects a net profit of 61.0 million to 73.0 million yuan for the first half of 2025, with a year-on-year increase of 35% to 62% [7] - Xinda Co. forecasts a net profit of 130.0 million to 150.0 million yuan for the first half of 2025, reflecting a substantial year-on-year growth of 2443.43% to 2834.73% [8] Group 4 - Shaanxi Coal Industry reported a coal production of 14.36 million tons in June, a year-on-year decrease of 5.07% [9] - Huanxu Electronics announced a consolidated revenue of 4.587 billion yuan in June, a year-on-year decline of 1.23% [10] Group 5 - Huadian International successfully issued 2.0 billion yuan in medium-term notes with a maturity of 3+N years and a coupon rate of 1.89% [20] - Zhongmin Energy reported a total power generation of 1.405 billion kilowatt-hours in the first half of 2025, a year-on-year decrease of 0.89% [20] Group 6 - Huaxia Biotech passed the FDA inspection with zero deficiencies, covering six major systems [21] - Ruikeda's application for convertible bond issuance has been accepted by the Shanghai Stock Exchange [22] Group 7 - Dafu Technology plans to invest no more than 100 million yuan in Anhui Yunta [42] - Tongda Co. won a bid for a project valued at 180.3 million yuan from the Southern Power Grid [46]

[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates significant performance growth in H1 2025, with revenue projected to increase by 18-24% and net profit attributable to shareholders by 35-62% H1 2025 Performance Forecast vs. Prior Year Comparison | Indicator | H1 2025 Forecast (CNY Millions) | H1 2024 Officially Disclosed (CNY Millions) | Year-over-Year Growth Rate | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 400 - 420 | 339.77 | 18% - 24% | | **Net Profit Attributable to Parent** | 61 - 73 | 45.05 | 35% - 62% | | **Net Profit Attributable to Parent (Excluding Non-Recurring Items)** | 55 - 65 | 36.54 | 51% - 78% | - These performance forecast figures are preliminary estimates by the company's finance department and have not been audited by a certified public accountant[2](index=2&type=chunk) [Prior Year Performance Review](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E4%B8%9A%E7%BB%A9%E6%83%85%E5%86%B5) This section presents H1 2024 performance as a comparative baseline, including operating revenue of approximately CNY 340 million and net profit attributable to parent of CNY 45.05 million H1 2024 Performance Overview | Indicator | Amount (CNY Millions) | | :--- | :--- | | **Operating Revenue** | 339.77 | | **Net Profit Attributable to Parent Company Shareholders** | 45.05 | | **Net Profit Attributable to Parent Company Shareholders (Excluding Non-Recurring Items)** | 36.54 | [Key Drivers of Current Period Performance Change](index=1&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8C%96%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) Performance growth is primarily driven by the company's focus on core business, enhanced marketing, and product innovation, leading to approximately 20% sales growth in key products - The company focused on its core separation, purification, and analytical testing businesses, continuously strengthening marketing, application technology development, and product iteration and innovation[4](index=4&type=chunk)[5](index=5&type=chunk) - Core businesses, including chromatographic packing and media products, achieved approximately **20% sales revenue growth** in the first half, significantly contributing to performance improvement[5](index=5&type=chunk) [Risk Warning](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company confirms no significant uncertainties have been identified that could impact the accuracy of this performance forecast - The company has not identified any significant uncertainties affecting the accuracy of this performance forecast[6](index=6&type=chunk) [Other Explanatory Matters](index=2&type=section&id=%E4%BA%94%E3%80%81%E5%85%B6%E4%BB%96%E8%AF%B4%E6%98%8E%E4%BA%8B%E9%A1%B9) Investors are reminded that the disclosed data are preliminary, and final financial figures will be based on the official H1 2025 report, with investment risks noted - The forecast data provided are preliminary, and specific financial figures will be subject to the company's officially disclosed H1 2025 report[7](index=7&type=chunk)